Navigation Links
ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
Date:8/19/2007

immuneregen.com" target="_new">http://www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre- clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended March 31, 2007 and on Form 10-KSB for the twelve months ended December 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements. Available Topic Expert(s): For information on t
'/>"/>

SOURCE ImmuneRegen BioSciences

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
5. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
8. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
9. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Tianyin Pharmaceutical Co., Inc., (NYSE Amex: ... and markets patented biopharmaceutical, modernized traditional Chinese medicine, ... the senior management will host a conference call ... financial results at 8:30 a.m. E.T. on Tuesday, ...
... LEIPZIG, Germany, Feb. 8, 2011 Data from the ... the SUPERA® stent for peripheral arterial disease (PAD) of ... Leipzig Interventional Course (LINC).  The SUPERA stent is CE ...  In the United States the SUPERA stent is the ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2011 Second Quarter Earnings Conference Call on Tuesday, February 15, 2011 at 8:30 a.m. E.T. 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 3
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... and have a reputation for being highly toxic, but when ... being being found to offer potential health benefits in a ... dementia. A new compound (AP39), designed and made at the ... by targeting delivery of very small amounts of the substance ... Scientists in Exeter have already found that the compound protects ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... French . Robot-assisted surgery dramatically improves outcomes ... researchers at the Jewish General Hospital,s Lady Davis Institute ... post-operative complications and shorter hospital stays, robotic procedures also ... late 2010 in a series of studies in ...
... , WEDNESDAY, Jan. 12 (HealthDay News) -- People who have ... after receiving the results, whether they are positive or negative, ... or get screening tests that might modify that risk, despite ... in the Jan. 13 issue of the New England ...
... of Science (AAAS) has elevated four Dartmouth professors to the ... Dartmouth Medical School. Medical School faculty members Charles ... MD, join Dartmouth biologist C. Robertson McClung among the 504 ... eight other Dartmouth researchers to have earned the distinction. ...
... Jan. 12 (HealthDay News) -- Research in rats suggests that ... by persistent ringing or other noises in the ears. ... a result of hearing loss. In this study, U.S. ... variety of sound tones over an extended period of time. ...
... cancer with a relatively high degree of accuracy when applied ... cancer, according to a study in the January issue of ... was performed at the University of Washington and Seattle Cancer ... with 592 patients who were recently diagnosed with breast cancer ...
... Scientists are reporting a scientific basis for the long-standing belief ... other countries can prevent and treat cataracts, a clouding of ... of vision loss worldwide. Their study appears in Inorganic ... Wu, Fu-Yung Huang, Shih-Hsiung Wu and colleagues note that eye ...
Cached Medicine News:Health News:Robotic surgery of 'tremendous benefit' to patients, say JGH researchers 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 3Health News:Dartmouth Medical School faculty named fellows of the American Association for the Advancement of Science 2Health News:Animal Study Finds Nerve Stimulation May Thwart Tinnitus 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: